We need to optimize piperacillin-tazobactam dosing in critically ill patients-but how?
Royal Brisbane and Women's Hospital, Brisbane, Australia.|School of Pharmacy, The University of Queensland, Brisbane, Australia.|School of Medicine, The University of Queensland, Brisbane, Australia.
Menino Osbert
MO
Cotta
Royal Brisbane and Women's Hospital, Brisbane, Australia.|School of Pharmacy, The University of Queensland, Brisbane, Australia.|School of Medicine, The University of Queensland, Brisbane, Australia.
Jason A
JA
Roberts
Royal Brisbane and Women's Hospital, Brisbane, Australia. j.lipman@uq.edu.au.|School of Medicine, The University of Queensland, Brisbane, Australia. j.lipman@uq.edu.au.|Queensland University of Technology, Brisbane, Australia. j.lipman@uq.edu.au.|The University of Witwatersrand, Johannesburg, South Africa. j.lipman@uq.edu.au.|Department of Intensive Care, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia. j.lipman@uq.edu.au.
Jeffrey
J
Lipman
D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D016638:Critical Illness; D006801:Humans; D010397:Penicillanic Acid / Q000008:administration & dosage; D010878:Piperacillin / Q000008:administration & dosage*
D000900:Anti-Bacterial Agents; D010397:Penicillanic Acid; D010878:Piperacillin